Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H1 2018

  • ID: 4464923
  • Drug Pipelines
  • 90 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • GlaxoSmithKline Plc
  • MORE
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H1 2018'; Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 20 molecules. Out of which approximately 20 molecules are developed by Companies.

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury.

It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.

The report 'Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 5, 8 and 1 respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Cardiovascular, Dermatology, Musculoskeletal Disorders and Oncology which include indications Multiple Sclerosis, Ulcerative Colitis, Autoimmune Disorders, Rheumatoid Arthritis, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis, Cardiovascular Disease, Cerebral Aneurysms, Colitis, Crohn's Disease (Regional Enteritis), Dermatological Disorders, Dermatomyositis, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Kidney Transplant Rejection, Primary Biliary Cirrhosis, Relapsing Multiple Sclerosis (RMS), Stroke and Systemic Lupus Erythematosus.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
  • The report reviews Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • GlaxoSmithKline Plc
  • MORE
Introduction

The Publisher's Report Coverage

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development

Actelion Pharmaceuticals Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celgene Corp

GlaxoSmithKline Plc

Idorsia Ltd

LG Chem Ltd

Novartis AG

Sanofi

Sun Pharma Advanced Research Company Ltd

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles

AKP-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-173717 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenerimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-9531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrasimod arginine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-253 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LC-510255 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIBR-0213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ozanimod hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ponesimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-247799 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCD-044 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

siponimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones

Featured News & Press Releases

Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City

Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis

Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis

Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS

Oct 19, 2017: Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Oct 16, 2017: Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG

May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis

Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology

Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis

Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis

Feb 09, 2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases

Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG

Oct 13, 2016: Celgene to Present New Data on Ozanimod at UEGW and ACG Congresses

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Actelion Pharmaceuticals Ltd, H1 2018

Pipeline by Arena Pharmaceuticals Inc, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Boston Pharmaceuticals Inc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Celgene Corp, H1 2018

Pipeline by GlaxoSmithKline Plc, H1 2018

Pipeline by Idorsia Ltd, H1 2018

Pipeline by LG Chem Ltd, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Sanofi, H1 2018

Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Actelion Pharmaceuticals Ltd
  • Arena Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • GlaxoSmithKline Plc
  • Idorsia Ltd
  • LG Chem Ltd
  • Novartis AG
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll